Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults …
YKO Teng, IN Bruce, B Diamond, RA Furie… - BMJ open, 2019 - bmjopen.bmj.com
Introduction Belimumab, an anti-B-lymphocyte-stimulator antibody, is approved for the
treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a …
treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a …
Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults …
YKO Teng, IN Bruce, B Diamond, RA Furie… - BMJ …, 2019 - pubmed.ncbi.nlm.nih.gov
Introduction Belimumab, an anti-B-lymphocyte-stimulator antibody, is approved for the
treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a …
treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a …
Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults …
YKO Teng, IN Bruce, B Diamond, RA Furie… - BMJ Open, 2019 - europepmc.org
Belimumab, an anti-B-lymphocyte-stimulator antibody, is approved for the treatment of
active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a B cell …
active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a B cell …
Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults …
YKO Teng, IN Bruce, B Diamond… - BMJ …, 2019 - scholarlypublications …
IntroductionBelimumab, an anti-B-lymphocyte-stimulator antibody, is approved for the
treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a …
treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a …
Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults …
YKO Teng, IN Bruce, B Diamond, RA Furie… - BMJ …, 2019 - search.proquest.com
Introduction Belimumab, an anti-B-lymphocytestimulator antibody, is approved for the
treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a …
treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a …
Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults …
YKO Teng, IN Bruce, B Diamond… - BMJ …, 2019 - researchinformation.amsterdamumc …
Introduction Belimumab, an anti-B-lymphocyte-stimulator antibody, is approved for the
treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a …
treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a …
Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults …
YKO Teng, IN Bruce, B Diamond, RA Furie… - BMJ …, 2019 - research.manchester.ac.uk
INTRODUCTION: Belimumab, an anti-B-lymphocyte-stimulator antibody, is approved for the
treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a …
treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a …
Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults …
YK Onno Teng, IN Bruce, B Diamond… - BMJ …, 2019 - academicworks.medicine.hofstra …
Abstract© 2019 Author (s)(or their employer (s)). Re-use permitted under CC BY-NC. No
commercial re-use. See rights and permissions. Published by BMJ. Introduction Belimumab …
commercial re-use. See rights and permissions. Published by BMJ. Introduction Belimumab …
[HTML][HTML] Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab …
YKO Teng, IN Bruce, B Diamond, RA Furie… - BMJ Open, 2019 - ncbi.nlm.nih.gov
Introduction Belimumab, an anti-B-lymphocytestimulator antibody, is approved for the
treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a …
treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a …
Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults …
YKO Teng, IN Bruce, B Diamond… - BMJ …, 2019 - scholarlypublications …
Introduction Belimumab, an anti-B-lymphocytestimulator antibody, is approved for the
treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a …
treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a …